Announced details
Early detection and screening of colorectal cancer, early diagnosis of tuberculosis, and healthcare settings
More than 90% of colorectal cancer cases are expected to be curable through early detection and treatment
The company’s colorectal cancer screening test is used in more than 50 countries worldwide
WHO (recommends and endorses TB-LAMP)
Chiyoda-ku, Tokyo (head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
WHO
| Item | Details |
|---|---|
| Names of Products / Services Covered | Colorectal cancer screening test, TB-LAMP tuberculosis molecular test method, Podcast ad “Supporting Global Health Through Colorectal Cancer Testing”, Podcast ad “Supporting Global Health Through Tuberculosis Testing” |
| Launch date | 1 April 2026 (distribution commenced; actual date) |
| Applicable area | Early detection and screening of colorectal cancer, early diagnosis of tuberculosis, and healthcare settings |
| Awarding / certifying body | WHO (recommends and endorses TB-LAMP) |
| Location | Chiyoda-ku, Tokyo (head office) |
| Quantitative Effects | More than 90% of colorectal cancer cases are expected to be curable through early detection and treatment |
| Usage history | The company’s colorectal cancer screening test is used in more than 50 countries worldwide |
| Source | WHO |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To clearly communicate the importance of testing through the early detection of diseases using in vitro diagnostic products, and the role its technology plays in supporting healthcare providers around the world.